OneAscent Family Office’s Regeneron Pharmaceuticals REGN Stock Holding History

OneAscent Family Office’s Portfolio REGN Stock Details REGN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$300K	Buy	+481	New	+$327K	0.15%	151

Other funds holding REGN

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Dodge & Cox San Francisco, California $191B AUM 17.5% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Nuveen Charlotte, North Carolina $419B AUM 43.02% 1-Year Est. Return

OneAscent Family Office's REGN Position: Q2 2026 in Review

OneAscent Family Office opened a new position in Regeneron Pharmaceuticals (REGN) in Q2 2026: 481 shares worth $300K. The stake represents 0.15% of the portfolio and ranks #151 among its holdings.

1,333 funds tracked by Wall St. Rank hold REGN as of Q2 2026.

OneAscent Family Office held 481 shares of Regeneron Pharmaceuticals worth $300K as of Q2 2026.
Regeneron Pharmaceuticals was a new OneAscent Family Office position in Q2 2026.
Regeneron Pharmaceuticals made up 0.15% of OneAscent Family Office's portfolio in Q2 2026, its #151 holding.
1,333 funds tracked by Wall St. Rank held Regeneron Pharmaceuticals as of Q2 2026.

Based on OneAscent Family Office's 13F filing for Q2 2026, filed 11 Aug 2026.